Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.

Lokugamage, Kumari G; Hage, Adam; de Vries, Maren; Valero-Jimenez, Ana M; Schindewolf, Craig; Dittmann, Meike; Rajsbaum, Ricardo; Menachery, Vineet D

Lokugamage, Kumari G; Hage, Adam; de Vries, Maren; Valero-Jimenez, Ana M; Schindewolf, Craig; Dittmann, Meike; Rajsbaum, Ricardo; Menachery, Vineet D.

Afiliación

Lokugamage KG; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Hage A; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
de Vries M; Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA.
Valero-Jimenez AM; Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA.
Schindewolf C; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Dittmann M; Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA.
Rajsbaum R; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Menachery VD; Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston TX, USA.

bioRxiv ; 2020 Jul 13.

Article en En | MEDLINE | ID: mdl-32511335

Palabras clave

2019-nCoV; COVID-19; Coronavirus; IFN; SARS-CoV; SARS-CoV-2; type I interferon

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: BioRxiv Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google